CNTA (Centessa Pharmaceuticals PLC) Bathi resik saben saham (EPS TTM)

Growth prospects for Centessa Pharmaceuticals (CNTA) depend on the ORX750 test results and interest from major corporations. The current EPS YoY TTM growth trend demonstrates price stability, while 1.60 shows the level of this metric. Financial stability relies on the development of sleep disorder therapies, although the company is engaged in a risky battle with global behemoths in the orphan diseases segment.
CNTA (Centessa Pharmaceuticals plc): rincian analitis lan laporan miturut indikator

The performance of Centessa Pharmaceuticals (CNTA) is reflected in the annual percentage growth of EPS TTM, which illustrates the monetization efficiency of its intellectual property and patent portfolio within the neurology sector. This indicator measures the rate of change in net income per share over a rolling year, allowing investors to assess the real growth rate of business value relative to the operating costs of developing new molecules.